Crossmark

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets

Crossref DOI link: https://doi.org/10.1038/s41388-018-0284-2

Published Online: 2018-05-11

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gates, Leah A.

Gu, Guowei

Chen, Yue

Rohira, Aarti D.

Lei, Jonathan T. https://orcid.org/0000-0002-0209-8051
Hamilton, Ross A.

Yu, Yang

Lonard, David M.

Wang, Jin https://orcid.org/0000-0003-3625-7919
Wang, Shu-Ping

Edwards, David G.

Lavere, Philip F.

Shao, Jiangyong

Yi, Ping

Jain, Antrix

Jung, Sung Yun

Malovannaya, Anna

Li, Shunqiang

Shao, Jieya

Roeder, Robert G.

Ellis, Matthew J.

Qin, Jun

Fuqua, Suzanne A. W.

O’Malley, Bert W.

Foulds, Charles E.
License Information

Text and Data Mining valid from 2018-05-11
More Information

Article History

Received: 12 May 2017

Revised: 2 April 2018

Accepted: 5 April 2018

First Online: 11 May 2018

Compliance with ethical standards

:

: B.W.O., D.M.L., J.W., A.D.R., Y.Y., and C.E.F. disclose an equity position in Coactigon, Inc.; M.J.E. received a consulting fee from AstraZeneca.